A 5-gene DNA methylation signature is a promising prognostic biomarker for early-stage cervical cancer

This study constructed a risk model based on a 5-DNA methylation signature for early-stage CC patients' survival prediction.What the implications are of these findings for clinical practice and/or further research? Methylated markers have the potential to discriminate patients of different risks and different OS. Our results may shed new light on the early diagnosis and intervention, and potential therapeutic targets for CC patients at pathological stages IA-IIA.PMID:34082663 | DOI:10.1080/01443615.2021.1907563
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research